Introduction
Trisomy 21 is a relatively common acquired aneuploidy observed in myeloid leukemia blasts. Furthermore, trisomy 21 predisposes individuals with Down syndrome (DS) to multiple hematologic abnormalities, including increased red cell volume, thrombocytosis in infancy, transient myeloproliferative disorder (TMD), and leukemia [1] [2] [3] .
While TMD and acute megakaryoblastic leukemia (AMKL) are associated with somatic GATA1 mutations [4] [5] [6] [7] [8] , little is known about how trisomy 21 impacts hematopoiesis, interacts with GATA1 mutations, or functions in leukemia.
Children with DS face a 10-20 fold greater risk of developing leukemia than other children, with acute lymphoblastic leukemia (ALL) and AMKL comprising the majority of cases. Relatively rare in the non-Down's population, AMKL occurs approximately 500 times more commonly in children with DS 9 , underscoring a strong association between trisomy 21, the genetic determinant of DS, and megakaryocytic malignancy. AMKL affects DS children before their fifth year and often follows a unique, spontaneously resolving TMD. TMD and AMKL both involve a clonal proliferation of megakaryoblasts, which are virtually indistinguishable between the two diseases;
however, TMD characteristically affects fetuses and neonates with DS and most often resolves spontaneously, while AMKL presents months to years later, requires chemotherapy, and is life-threatening. The ontogeny of DS-AMKL supports a model in which AMKL derives from an original TMD clone after additional mutations are acquired.
If trisomy 21 is considered the first genetic event in DS-AMKL leukemogenesis, the second is likely to be mutation of the gene for GATA1, an X-linked, blood-specific only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From transcription factor essential for development of the erythroid and megakaryocytic lineages. Both TMD and AMKL blasts harbor somatic GATA1 mutations which result in the exclusive generation of GATA1s [4] [5] [6] [7] [8] , a shorter GATA1 isoform that retains both DNA binding zinc fingers, but lacks the N-terminal transcriptional activation domain 10 . Normal human hematopoietic cells produce GATA1s in addition to the full length protein, but its functions in normal and malignant hematopoiesis remain poorly understood.
Interestingly, wild type mice do not express detectable levels of Gata1s 11 (and our unpublished data); however, mice have been engineered to express the shorter protein in place of full length GATA1. These latter animals are affected by hyperproliferation of a yolk sac/fetal liver progenitor, which resolves and gives way to apparently normal hematopoiesis in adult mice 12 .
In contrast, humans with germline mutations that cause the exclusive expression of GATA1s suffer more severe consequences throughout their lifetimes, including anemia, trilineage dysplasia, and hyperproliferation of dysplastic megakaryocytes 13 . Importantly, exclusive GATA1s production alone does not cause leukemia in either humans or mice 12, 13 . These key findings illustrate a requisite role for additional genetic events in DS-AMKL and refocus attention on the potential cooperating function of trisomy 21 in DS leukemogenesis.
Presumably, overexpression of one or more genes on chromosome 21 makes hematopoietic cells vulnerable to transformation; however, because the number of trisomic genes is large in most cases of DS -chromosome 21 encodes 364 known genes, the developmental and malignant contributions of specific genes in the hematopoietic system are difficult to tease apart. Several studies have attempted to correlate DS traits with regions of chromosome 21 by examining the DS phenotypes affecting individuals only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From with various partial chromosome 21 trisomies. These reports have helped shape a "Down syndrome critical region" (DSCR) hypothesis, which predicts that most of the common DS phenotypes can be assigned to a small region of chromosome 21. This region extends about 5 Mb from DS21S17 to Mx1 and has been implicated in multiple DS phenotypes, including mental retardation, short stature, craniofacial anomalies, and hypotonia.
Recently this region has been shown to be necessary, but not sufficient for the craniofacial characteristics observed in mouse models of DS, underscoring the complexity of gene interactions in DS 14 . No such "critical region" has been reported for the increased incidence of leukemia in DS. A small increase in disomic homozygosity at 21q11. To investigate the effects of trisomy 21 on blood cell development, and a potential role in malignancy, we studied the hematopoietic system in the Ts65Dn mouse model of DS. Ts65Dn mice are the most widely used model for DS and display many of the only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From features common to human DS, including craniofacial characteristics, learning deficits, and heart malformations [20] [21] [22] [23] [24] . Ts65Dn mice harbor a segmental trisomy for the distal end of chromosome 16q fused to a gene poor region of 17p. The 16q breakpoint is distal to Ncam2 and proximal to Gapba, and the 15.6 Mb trisomic region encodes 104 conserved genes, including an estimated 94 of the highly conserved 170 orthologs from the Down syndrome critical region (Supplemental Table 1 ). Hematopoiesis has not been extensively studied in the Ts65Dn strain, although one report has detailed decreased proliferation of CD34-positive cells in vitro 27 . Notably, leukemia has never been reported in these 
Colony assays
Single cell suspensions were obtained from bone marrow or spleen in cold PBS + 1%
BSA. Red cells were lysed in hypotonic KCl and nucleated cells were washed and plated in M3234 methylcellulose for BFU-E and CFU-GM, or MegaCult-C for CFU-MK (Stem Cell Technologies, Inc.), supplemented with Epo, IL3, IL6, IL11, SCF, Tpo, and/or GMCSF. 15,000 cells/ml were plated for BFU-E and CFU-GM, and 30,000 cells/ml for CFU-MK. Cells were cultured for 3-8 days at 37 degrees and 5% CO 2 and colonies were enumerated. CFU-MK cultures were fixed and stained with acetylcholiniodide according to the manufacturer's specifications and acetylcholinesterase positive colonies were counted.
Flow cytometry
Single cell suspensions from bone marrow or spleen were treated with hypotonic KCL to lyse red cells. Cells were washed and stained in PBS+1%BSA+5%NGS on ice for 1 hour 
Transplantation Assays
Eight-to ten-week old lethally irradiated (600 + 400 rads) recipient mice (C57Bl/6 Ly 5.1, from Jackson Laboratories, stock number 002014) received 10 6 nucleated bone marrow cells from 8-10 week old Ts65Dn mice (C3H/Bl6 background Ly5.2) through the retroorbital sinus. n=5 Ts65Dn recipients; n=5 control recipients. Mice were maintained on Bactrim water from one week prior to irradiation and for the duration of the experiment.
only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
Results

Ts65Dn mice develop multiple peripheral blood abnormalities
To establish baseline hematopoietic parameters for the Ts65Dn strain, monthly peripheral complete blood counts (CBC) were performed for 14 Ts65Dn animals and 22 same sex euploid littermate controls for 15 months. CBC data reveal the development of progressive thrombocytosis in Ts65Dn mice, with platelet numbers double to triple those of controls by 12 months of age ( Figure 1A and Supplemental Table 2 ). Platelet counts were significantly different between the groups at every time point examined.
Additionally, Ts65Dn mice present with significantly diminished erythrocyte numbers and elevated mean corpuscular volume (MCV) values, indicating larger red blood cell size, and lower hemoglobin concentrations ( Figure 1A and Supplemental Table 2 ). As humans with DS also display such erythroid macrocytosis 1 , these data suggest that Ts65Dn mice share some features of hematopoiesis with human DS. To investigate whether a folate deficiency was the cause of macrocytosis, we measured folate levels in control and Ts65Dn peripheral blood erythrocytes and plasma, but did not detect significant differences (Supplemental Table 3 ). Mice also displayed mildly increased numbers of white blood cells, monocytes, lymphocytes, and neutrophils for the first 12 months (Supplemental Table 2 ).
Bone marrow and spleen from Ts65Dn mice show several abnormalities reminiscent of human chronic idiopathic myelofibrosis
To investigate the basis for the peripheral blood phenotype, mice were sacrificed for further study at 14 to 15 months of age. Histological examination of bone marrow In vitro colony forming assays were next used to assess the number of hematopoietic progenitors in Ts65Dn bone marrow and spleen. Ts65Dn mice displayed a trend toward increased numbers of erythroid, granulocyte-macrophage, and megakaryocytic progenitors in the spleen, consistent with extramedullary hematopoiesis only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From (Figure 3 ). These data are not significant, likely owing to the disparate severity of disease and large variability of colony number between Ts65Dn animals. The colony forming assays from the bone marrow yielded results that were more variable and most likely a consequence of variation in disease severity and degree of bone marrow fibrosis.
Importantly, we did not detect mutations in Gata1, Jak2, or Jak3 analogous to those seen in people with DS-AMKL or MPD (data not shown). Our data demonstrate that Ts65Dn mice develop a phenotype which can be classified by the Bethesda criteria as a myeloproliferative disease, manifest as megakaryocyte and granulocytic hyperplasia with bone marrow fibrosis and extramedullary hematopoiesis 26 .
Hematopoietic stem and progenitor compartment profiles are distorted in Ts65Dn mice
The myeloproliferative diseases are clonal disorders of the hematopoietic stem and progenitor compartments. To determine whether the myeloproliferative phenotype For Figure 5C ). Additionally, a shift in the progenitor compartment was evident, with a relative increase in the GMP fraction and a decrease in the MEP compartment ( Figure   5D ). These data demonstrate that the development of myeloproliferative disease in Ts65Dn is progressive and initiates in relatively young mice, with obvious evidence of disease by 4 months of age.
Transplantability
The ability to give rise to transplantable tumors can be useful in distinguishing neoplasms from a reactive condition. Although transplantability often correlates with the degree of malignancy, not all malignancies are transplantable 26 . To assess whether defects observed in Ts65Dn are cell autonomous, we reconstituted eight-to ten-week old lethally irradiated C57Bl/6 recipients with 10 6 nucleated bone marrow cells from Ts65Dn
animals. All recipients analyzed demonstrated substantial engraftment by expression of the CD45.2 marker at 3 months post-transplant; however, only 2 of 5 Ts65Dn bone marrow recipients survived to 6 months post-transplant, in contrast to 5 of 5 control recipients, indicating weaker long-term repopulating ability in Ts65Dn bone marrow.
(Supplemental Figure 1) . There was no evidence of thrombocytosis by CBC for Ts65Dn recipients by six months post-transplant, although at this timepoint, the sample size was small. Interestingly, Ts65Dn transplant recipients did display macrocytosis, indicating that this defect may occur by a cell autonomous mechanism. (Supplemental Table 4 ).
Increased dosage of Aml1/Runx1 is not required for Ts65Dn myelofibrosis and megakaryocytic hyperplasia
The trisomic region in Ts65Dn mice encodes 104 known genes. One of these, Aml1/Runx1 is an attractive candidate oncogene in DS leukemogenesis as it has an established function in hematopoietic stem cell development, megakaryopoiesis, and 
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Ts65Dn mice proliferate to a lesser extent in vitro than controls, supporting the hypothesis that these mice have fewer long-term repopulating cells in the bone marrow 28 .
The profile of myeloid progenitor cells is also skewed in Ts65Dn bone marrow, with an increased proportion of GMPs, and dramatically reduced MEP component. It may be of interest that GMPs are distinguished from MEPs in part by increased expression of CD34, although it is unclear whether this relates to increased CD34 expression on Ts65Dn LSK cells. A similar expansion in GMPs has also been documented in the blast crisis phase of human MPD 29, 30 . Our data suggest that Ts65Dn mice develop a disease with significant similarities to human MPD and roots in the hematopoietic stem and myeloid progenitor compartments.
Two of the most well understood molecular causes of human myeloproliferative disease are the V617F activating mutation in the tyrosine kinase JAK2 and the Philadelphia chromosome. The V617F JAK2 mutation, present in 90% of PV patients and 30-50% of ET and CIMF patients, leads to constitutive activation of multiple signaling pathways including Stat, PI3K, and MAPK [31] [32] [33] [34] [35] . Additionally, the homologous factor JAK3 is mutated in a subset of DS-AMKL. The BCR-Abl fusion protein generated by the Philadelphia chromosome constitutively activates the CRKL adaptor and multiple downstream pathways 36 . Notably, we did not detect analogous Jak2 or Jak3 mutations in Ts65Dn bone marrow and no cytogenetic abnormalities were detected (data not shown).
Therefore, our data may provide insight into genetic factors capable of causing Phmyeloproliferative disease in patients who lack JAK2 mutations. Furthermore, because JAK2 mutations likely require cooperating events in MPD, these animals may provide insights into these unknown secondary factors.
For Overall, our data demonstrate that Ts65Dn mice are a useful model for hematopoiesis in Down syndrome and reveal the potential of chromosome 21 genes to promote megakaryocyte hyperproliferation and myeloproliferative disease. Further studies to better define the pathology of this phenotype and determine the specific genes that promote it will improve understanding of human myeloproliferative disease and hematologic abnormalities in DS.
Acknowledgments
We thank Dr. James Downing for Aml1/Runx1 heterozygous knockout mice, GK contributed to experimental design, performed the research, analyzed the data, and wrote the paper SJ contributed to performing the research HL contributed to performing the research ED contributed to performing the research SG contributed to analyzing the data and writing the paper MML contributed to analyzing the data and writing the paper JDC designed the research, analyzed and interpreted data, and contributed to writing the paper only. and bone marrow reticulin staining (bottom panels) demonstrate that Ts65Dn mice with three or two alleles of Runx1 (Ts65Dn/Runx1+++ and Ts65Dn/Runx1++-, respectively) develop a similar phenotype. B) In vitro colony forming assays demonstrate that restoring disomy at the Runx1 locus does not abrogate extramedullary hematopoiesis in Ts65Dn. Runx1 trisomy may contribute to the extent of extramedullary megakaryopoiesis.
